NSP-5033 / Novostar Pharma - LARVOL DELTA

Discovery of NSP-5033: A novel and potent PARP7/12 dual inhibitor (AACR 2024) - "With excellent ADME and pharmacokinetic properties, NSP-5033 demonstrated potent in vivo efficacy in human lung cancer xenografts with tumor regression and induced antitumor immunity in tumor-bearing immunocompetent mice. NSP-5033 has been nominated as a preclinival candidate for treatment of solid tumors and is undergoing IND-enabling studies."

Lung Cancer • Oncology • Solid Tumor • CXCL10 • IFNB1 • PARP12 • TIPARP